Literature DB >> 26956157

Mechanism of action of cariprazine.

Stephen M Stahl.   

Abstract

Cariprazine is a new therapeutic agent recently approved for the treatment of both schizophrenia and manic or mixed episodes associated with bipolar disorder, and is under investigation for the treatment of both bipolar depression and major depressive disorder.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26956157     DOI: 10.1017/S1092852916000043

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  19 in total

Review 1.  Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.

Authors:  Massimo Carlo Mauri; Silvia Paletta; Chiara Di Pace; Alessandra Reggiori; Giovanna Cirnigliaro; Isabel Valli; Alfredo Carlo Altamura
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

Review 2.  Brexpiprazole: A Review in Schizophrenia.

Authors:  James E Frampton
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

3.  The prospects of cariprazine in the treatment of schizophrenia.

Authors:  Jonathan R Scarff
Journal:  Ther Adv Psychopharmacol       Date:  2017-08-28

Review 4.  New Antipsychotic Medications in the Last Decade.

Authors:  Mehak Pahwa; Ahmad Sleem; Omar H Elsayed; Megan Elizabeth Good; Rif S El-Mallakh
Journal:  Curr Psychiatry Rep       Date:  2021-11-29       Impact factor: 5.285

5.  Cariprazine Use in Combination With a Mood Stabilizer in First Episode Mania.

Authors:  Roberto Palacios-Garrán; Vicent Llorca-Bofí; Gara Arteaga-Henriquez; Enrique Del Agua
Journal:  Front Psychiatry       Date:  2022-05-11       Impact factor: 5.435

Review 6.  Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults.

Authors:  Amber Edinoff; Miriam T Ruoff; Yahya T Ghaffar; Arthur Rezayev; Devanshi Jani; Adam M Kaye; Elyse M Cornett; Alan D Kaye; Omar Viswanath; Ivan Urits
Journal:  Psychopharmacol Bull       Date:  2020-09-14

7.  Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model.

Authors:  Vanja Duric; Mounira Banasr; Tina Franklin; Ashley Lepack; Nika Adham; Béla Kiss; István Gyertyán; Ronald S Duman
Journal:  Int J Neuropsychopharmacol       Date:  2017-10-01       Impact factor: 5.176

8.  Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?

Authors:  Nefize Yalin; Allan H Young
Journal:  Neuropsychiatr Dis Treat       Date:  2020-06-09       Impact factor: 2.570

Review 9.  Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety.

Authors:  István Laszlovszky; Ágota Barabássy; György Németh
Journal:  Adv Ther       Date:  2021-06-06       Impact factor: 3.845

10.  Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study.

Authors:  Jia Jun Weng; Li Hua Wang; Hao Zhu; Wen Rong Xu; Yu Mei Wei; Zhi Yang Wang; Wen Juan Yu; Hua Fang Li
Journal:  Neuropsychiatr Dis Treat       Date:  2019-08-07       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.